ADIL

Adial Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website adialpharma.com
Employees(FY) 16
ISIN US00688A2050

Performance

-1.83%

+5.94%

+1.9%

-15.75%

-42.47%

YTD

-38.15%

Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Advanced Technical Analysis

Technical Analysis of ADIL 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23, the Oscillators Score at 43 indicating a neutral stance, and the Technical Score at 33 reinforcing the bearish outlook. This combination suggests a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ADIL

Stock Rank

Recent News & Updates

2024-12-02 19:30
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations(Globenewswire)
2024-12-02 19:00
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations(Yahoo Finance)
2024-11-24 23:00
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know(Yahoo Finance)
2024-11-13 19:30
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-11-13 19:00
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder(Yahoo Finance)
2024-11-12 19:30
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-04 19:30
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer(Globenewswire)
2024-10-22 21:00
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference(Globenewswire)
2024-10-16 21:00
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company's Genetic Diagnostic for Addiction Treatment(Globenewswire)
2024-10-16 20:30
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate(Yahoo Finance)
2024-10-14 21:00
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery(Globenewswire)
2024-09-18 20:30
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-09-03 21:00
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-13 20:30
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-08-12 21:00
Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04(Globenewswire)
2024-08-12 20:30
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder(Yahoo Finance)
2024-08-06 21:00
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-08-06 20:30
EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4(Yahoo Finance)
2024-07-30 20:30
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044(Globenewswire)
2024-07-22 20:30
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-07-22 20:00
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder(Yahoo Finance)
2024-06-26 17:52
ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023(Investorplace)
2024-06-19 20:30
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-06-19 20:00
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder(Yahoo Finance)
2024-06-05 19:00
MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies(Accesswire)
2024-06-05 03:17
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025(Investorplace)
2024-06-04 20:30
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder(Globenewswire)
2024-06-04 20:00
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder(Yahoo Finance)
2024-05-28 20:30
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th(Globenewswire)
2024-05-14 21:54
ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024(Investorplace)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.